Study to Compare Zoladex™ 10.8 mg With Zoladex 3.6 mg in Pre-menopausal Women With Breast Cancer
Status:
Completed
Trial end date:
2017-11-20
Target enrollment:
Participant gender:
Summary
The purpose of this study is to examine the efficacy and safety as well as the
characteristics of the female hormone and study medications after administration in
pre-menopausal women with estrogen receptor positive advanced breast cancer who were
randomised in a 1:1 ratio to either of the two treatment groups; the ZD9393 3.6 mg depot
group or ZD9393 10.8 mg depot group, both given in combination with tamoxifen tablets.